Aclaris Therapeutics (ACRS): Bullish KOL Call - JMP

JMP Securities analyst, Donald Ellis, reiterated his Market Outperform rating on shares of Aclaris Therapeutis (NASDAQ: ACRS) after hosting a KOL call with Dr. Ted Rosen to discuss A-101’s opportunity in SK, common warts (CW), and Molluscum Contagiosum (MC).

The analyst stated that Dr. Rosen was highly positive and expects rapid adoption for SK followed closely by off-label use in CW and MC due in part to A-101’s safety profile and high clearance
and almost-clearance rates that appear to have acceptable efficacy.

No change to the price target of $39.

For an analyst ratings summary and ratings history on Aclaris Therapeutis click here. For more ratings news on Aclaris Therapeutis click here.

Shares of Aclaris Therapeutis closed at $27.38 yesterday.

You May Also Be Interested In

• Aclaris Therapeutis (ACRS) Reiterated at Overweight by Cantor Fitzgerald Post Tilrekimig Ph2 Data
• Constellation Energy (CEG) PT Lowered to $350 at BMO Capital
• Nike (NKE) PT Lowered to $19 at BNP Paribas Exane, 'The only positive we see is that Nike will cede $4bn of revenues to emerging brands'